BSECompany UpdateM&A1h ago
Sudarshan Pharma Industries Ltd
We hereby submit the presentation on the manufacturing plant proposed to be acquired by the Company.
Sudarshan Pharma Industries Ltd submitted a presentation on the proposed acquisition of a manufacturing plant. The plant is located 40km from Visakhapatnam Airport and spans 14 acres. It is engaged in manufacturing API and API Intermediates, with approvals from DCA, WHO, USFDA, and ANVISA. The facility has a workforce of 200 employees and operates 24/7.
BSECompany UpdateDivestiture20h ago
Sudarshan Pharma Industries Ltd
The Board of Directors at their Meeting held on 12/August/2026 approved the divestment of 2,09,100 equity shares (51.00% of paid up share capital) of Ishwari Healthcare Private Limited. ....
Sudarshan Pharma Industries Ltd has approved the divestment of 2,09,100 equity shares (51.00% of paid up share capital) of Ishwari Healthcare Private Limited, a subsidiary, equivalent to 51.00% of the paid-up equity share capital of Ishwari Healthcare. Upon completion of the divestment, Ishwari Healthcare would cease to be a subsidiary of the Company.
BSECompany UpdateM&A20h ago
Sudarshan Pharma Industries Ltd
The Board of Directors at their meeting held on 12/August/2026 approved to acquire 3,000 equity shares (30.00% of paid up capital) of Sudarshan Maven Pharma Private Limited. Upon acqusition, ....
Sudarshan Pharma Industries Ltd has approved the acquisition of 30% stake in its subsidiary Sudarshan Maven Pharma Private Limited for Rs. 3,000,000.
BSEResultResults1d ago
Sudarshan Pharma Industries Ltd
Please find attached the Unaudited Standalone and Consolidated Financial Results for the quarter ended 30/06/2026
Sudarshan Pharma Industries Ltd has announced its unaudited standalone and consolidated financial results for the quarter ended June 30, 2026, with a net profit of ₹604.18 lakhs and a revenue from operations of ₹16,566.03 lakhs.
BSEInsider Trading / SASTPledge4d ago
Sudarshan Pharma Industries Ltd
The Exchange has received Disclosure under Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 on August 08, 2026 for Hemal Vasantrai Mehta
Sudarshan Pharma Industries Ltd has made a disclosure under Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011, regarding the un-pledge of shares held by Mr. Hemal Mehta, a promoter of the company.
BSEBoard MeetingResults4d ago
Sudarshan Pharma Industries Ltd
Sudarshan Pharma Industries Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 12/08/2026 ,inter alia, to consider and approve Unaudited Standalone ....
Sudarshan Pharma Industries Ltd has informed BSE that the meeting of the Board of Directors is scheduled on 12/08/2026 to consider and approve Unaudited Standalone Financial Results for the quarter ended 30/06/2026.